Deliver Your News to the World

(SmallCapNewsRelease: SPPH) Initiates Phase I For Its Proprietary Formulation “Metformin”


JERICHO, NY—(SmallCapNewsRelease)—October 28th, 2010, Spencer Pharmaceutical Inc. (OTC: SPPH) announced today that their Met4 (Metformin) findings are being sent to an independent lab to be validated.

As per the company’s guidance released on October 13th, 2010, Spencer Pharmaceuticals will be utilizing an independent lab to begin testing of Met4 on laboratory animals. By using an independent lab, Spencer Pharmaceuticals believes the independent testing will not only bring more attention to the company’s efforts, but will add value by aiding in future licensing deals.

Spencer Pharmaceutical Inc. is a US-based Pharmaceutical Research and Development Corporation, which is developing innovative drug release and absorption systems for the treatment of metabolic diseases such as diabetes and metabolic syndrome.

The company believes that Met4 will obtain fast track approval, giving the company a foothold in the $4 billion Metformin market.

For more information, please visit

To view the entire press release, please visit

SmallCapNewsRelease gainers are China Grentech Corp (NASDAQ: GRRF) Eltek Ltd (NASDAQ: ELTK) MER Telemanagement Solutions (NASDAQ: MTSL) BMP Sunstone Corp (NASDAQ: BJGP) Syniverse Holdings (NYSE: SVR) 3D Systems Corp (NASDAQ: TDSC) Chart Industries Inc (NASDAQ: GTLS) Renaissance Learning Inc (NASDAQ: RLRN)

SmallCapNewsRelease decliners are Flagstar Bancorp (NYSE: FBC) Clean Diesel Technologies (NASDAQ: CDTID) Oclaro Inc (NASDAQ: OCLR) Sourcefire (NASDAQ: FIRE) Cray Inc (NASDAQ: CRAY) Navigant Consulting Inc (NYSE: NCI) Revlon Inc (NYSE: REV) Integrated Silicon Solution (NASDAQ: ISSI)

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid Small Cap News Release twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation, do no trading of any kind and send no faxes or emails.


 Clinical Trial

This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.